Scientists at Dana-Farber Cancer Institute report they have blocked the development of prostate tumors in cancer-prone mice by knocking out a molecular unit they describe as a "powerhouse" that drives runaway cell growth.

A compound that accumulates in cells more readily than a commonly used colorectal cancer drug may be just as useful in treating colorectal tumors, but with fewer side effects, MIT researchers have found.

Synthetic molecules designed by two Hebrew University of Jerusalem researchers have succeeded in reducing and even eliminating the growth of human malignant tissues in mice, while having no toxic effects on normal tissue.

A critical enzyme used to prepare a powerful cancer-killing agent may be able to help drug makers better target the cells the natural product attacks, according to findings published in the May 23 edition of the Journal of Biological Chemistry.

The gene that allows fireflies to flash is helping researchers track the effectiveness of anti-cancer drugs over time.

New data from an international, multicenter Phase III clinical trial has found that the experimental targeted therapy everolimus (RAD001) significantly delays cancer progression in patients with metastatic kidney cancer whose disease had worsened on other treatments.

Gefitinib, the once-promising drug formerly approved as a second line treatment for lung cancer, also known as Iressa, enhanced the effectiveness of hormonal therapy for the treatment of specific types of metastatic breast cancer, according to a Phase II clinical trial led by researchers at The University of Texas M. D. Anderson Cancer Center.

Combining natural organic atoms with metal complexes, scientists at The Wistar Institute have developed a new type of enzyme inhibitor capable of blocking a biochemical pathway that plays a key role in cancer development.

Heart damage from certain anti-cancer drugs no longer should be regarded as a rare or relatively unimportant complication, scientists in Italy have concluded in a new overview of research on the cardiotoxicity of anti-cancer drugs.

The first analysis of the genetic determinants of resistance to the anti-cancer drug methotrexate in childhood acute lymphoblastic leukemia (ALL) could offer a pathway to predicting such resistance and treatments to overcome it, according to a St. Jude Children’s Research Hospital study.

Researchers from the Nano Machine Center at the California NanoSystems Institute at UCLA have developed a novel type of nanomachine that can capture and store anticancer drugs inside tiny pores and release them into cancer cells in response to light.

Researchers at the National Sun Yat-Sen University and Kaohsiung Medical University, Kaohsiung, Taiwan have revealed a new mechanism by which nonsteroidal anti-inflammatory drugs (NSAIDs) attenuate tumor invasion and metastasis. The research, to be published in the April 2008 issue of Experimental Biology and Medicine, provides new insights for the understanding of the anti-cancer effects of NSAIDs.